135th Annual Shattuck Lecture — GLP-1: Discovery and Impact on Health
Saturday, May 17, 2025, 12:45-1:45 p.m. EST
Live In-Person & Virtual
Joel F. Habener, MD
Joel F. Habener, MD, is Professor of Medicine (emeritus) at the Harvard Medical School, Honorary Scientist at the Massachusetts General Hospital, and a former Investigator with the Howard Hughes Medical Institute.
Dr. Habener is a discoverer of the insulinotropic hormone glucagon-like peptide-1, cyclic AMP response element binding protein, the islet duodenal homeodomain protein, and the existence of multipotent stem cells in the pancreas. Dr. Habener's discoveries
contributed to the development of glucagon-like peptide-1, currently on the market as a treatment for diabetes.
Dr. Habener has been elected into a number of societies including the Association of American Physicians, National Academy of Sciences, and the National Academy of Inventors. He is the recipient of several awards, including more recently the Harrington
Prize for Innovation in Medicine, Warren Alpert Foundation Prize, Harvard Medical School (2020), Canada Gairdner International Award (2021), VinFuture Foundation Prize for outstanding achievements in emerging fields (2023), Time100 List of 100 most
influential people in the world (2024), Tang Prize in Biopharmaceutical Sciences (2024), Lasker-DeBakey Clinical Medical Research Award (2024), Princess of Asturias Award for Technical and Scientific Research (2024), Lifetime Achievement Award, Stanford
Drug Discovery Symposium (2025), BBVA Foundation Frontiers of Knowledge Award in In Biology and Biomedicine (2025) and many others.
Julie R. Ingelfinger, MD
Julie R. Ingelfinger, MD, is a professor of pediatrics at Harvard Medical School, senior consultant in pediatric nephrology at Mass General for Children at Massachusetts General Brigham, and a deputy editor of the New England Journal of Medicine.
She has been a consultative pediatric nephrologist, hypertension specialist and mentor in these areas for several decades. Her commitment to teaching is reflected in the multiple awards she has received. These include the Henry L. Barnett award from
the American Academy of Pediatrics (2009), the Founders Award from the American Society of Pediatric Nephrology (2012), the National Kidney Foundation’s Honors Award (2018), and an alumni achievement award from Albert Einstein College of Medicine
(2018).
For many years, Dr. Ingelfinger has been involved in studies of the intrarenal renin angiotensin aldosterone system (RAAS), perinatal programming, diabetic nephropathy and the interaction of the coagulation pathways and microvascular disease. Her current
projects focus on the role of the intrarenal vasoactive pathways in disease states and the role of maternal nutrition in kidney development and perinatal programming.
Interested in innovative ways to teach writing and communication, Dr. Ingelfinger has been an editor of the textbook Pediatric Hypertension, in each of its 5 editions.
Clifford Rosen, MD
Dr. Rosen is an endocrinologist and translational bone biologist. He currently oversees the Rosen Musculoskeletal Laboratory at the Maine Medical Center. In the last ten years, the Rosen laboratory has been studying bone marrow stem cell fate with particular
reference to the switch between pre-adipocytes and pre-osteoblasts, and with a focus on the bioenergetic programs of those progenitors. He is a multi-PI on the U19 renewal studying brain aging, FSH and bone loss. Dr. Rosen is the Principal Investigator
for the Northern New England Clinical and Translational Research Network (U54) that stresses clinical translation of basic investigations. Dr. Rosen is also the Director of the Physiology Core of a P20 COBRE and co-director of the Mesenchymal and
Neural Regulation of Metabolic Networks (NIGMS). More recently Dr. Rosen is the multi-PI for the ISCORE Network of NIH funded IDeA states research in Long COVID, termed RECOVER. He also directs the MaineHealth RECOVER site and has been studying the
Pathobiology of Long COVID, examining the role of viral persistence in adipose tissue. . He is the past president of the American Society of Bone and Mineral Research and recently finished a four-year term as council member of the National Advisory
Committee on Aging (NIA). He previously served a four-year term on the NIAMS Advisory Council and as a Board member of the Endocrine Society. He has been an Associate Editor at New England Journal of Medicine for 10 years, and previously a
Senior Editor at eLife. Dr. Rosen has published more than 600 peer-reviewed publications in Journals such as Nature, Nature Medicine, Cell, Cell Metabolism, PNAS, New England Journal of Medicine, Journal of Clinical Investigation, and
The Lancet.
Eric J. Rubin, MD, PhD
Eric J. Rubin, M.D., Ph.D., has been Editor-in-Chief at the New England Journal of Medicine and NEJM Group since 2019, after serving as an NEJM Associate Editor for several years. As an Associate Physician specializing in tuberculosis, Dr.
Rubin sees patients at Brigham & Women’s Hospital in Boston.
Dr. Rubin is also a Professor of Medicine at the Harvard Medical School and continues his lab work at the Harvard T.H. Chan School of Public Health, where he is an Adjunct Professor. He is a Fellow of the American Academy of Microbiology, a member of
the National Academy of Medicine and a member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC).
Previously, Dr. Rubin was a resident and clinical fellow at Massachusetts General Hospital and a postdoctoral fellow at Harvard Medical School. He was the Irene Heinz Given Professor and Chair of the Department of Immunology and Infectious Disease at
Harvard T.H. Chan School of Public Health before joining NEJM. Dr. Rubin earned an A.B. degree from Harvard as well as M.D. and Ph.D. degrees from Tufts University.
